 NEW YORK and CLEVELAND, Oct. 13, 2021 GLOBE NEWSWIRE -- Abeona Therapeutics Inc. Nasdaq: ABEO, a fully-integrated leader in gene and cell therapy, today announced two presentations of previously disclosed clinical data at upcoming scientific congresses in October 2021. The presentations include a poster presentation on the long-term wound healing and pain relief data from the Phase 12a EB-101 trial at the 2021 Pediatric Dermatology Research Alliance PeDRA Annual Conference, held virtually October 14-15, 2021; and an oral presentation on the pivotal trial of the Companys investigational AAV-based gene therapy ABO-102 in MPS IIIA at the virtual 28th Annual Congress of the European Society of Gene Cell Therapy ESGCT, October 19-22, 2021. 